A5051643698- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
- Mitochondrial Function and Pathology
- Cancer-related Molecular Pathways
- MRI in cancer diagnosis
- Adipose Tissue and Metabolism
- Radiomics and Machine Learning in Medical Imaging
Sağlık Bilimleri Üniversitesi
2025
University of Health Science
2025
Sivas State Hospital
2022
CDK4/6 inhibitors have changed the landscape of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (BC) management. It is essential to identify predictive and prognostic factors for efficacy inhibitors. We aimed investigate differences in characteristics outcomes patients receiving first-line according PgR status. This multicenter retrospective study included 351 treated with CDK 4/6 HR-positive/HER2-negative BC. Patients were categorized...
Introduction: CDK 4/6 inhibitors are effectively utilized among patients with hormone-positive, HER-2-negative metastatic breast cancer. The dose reduction for these varies between 35% and 57% across multiple trials. We aim to clarify the characteristics of who had dosage effect this on survival outcomes. Materials Methods: study was designed as a retrospective, multicenter study. Patients received in first-line subsequent treatment settings were grouped based reductions. Progression-free...
Introduction: The aim of this study is to investigate the relationship between irisin, a new test with similar effects on energy metabolism and thermogenesis, thyroid hormones. Material Methods: 86 subjects included in study. were divided into three groups as euthyroid, hypothyroid hyperthyroid group by evaluating their TSH fT4 levels. For all subjects, gender, age, medical history blood results examined. Irisin levels measured. Statistical analysis was performed obtained data. Results: A...